• ͬÆÚÁ½ÆªÒ½Ñ§¼ìÑé¶¥¿¯
    BGÕæÈËÐ¡¸Æµ°°×¼²²¡ÌØÒìÐÔÑо¿È¡µÃÖØ´óÍ»ÆÆ

    kv_1

    ½üÈÕ£¬BGÕæÈ˺ÍÎ人ÑÇÖÞÐÄÔಡҽԺ×÷Ϊ¹²Í¬µÚÒ»×÷Õßµ¥Î»£¬ÁªºÏ·ÒÀ¼º£ëÄ¡¢Ð¡¸Æµ°°×¹ú¼Ê¶¥¼¶×¨¼Ò Fred S. Apple ½ÌÊÚ£¬ÔÚÈ«Çòҽѧ¼ìÑéȨÍþÔÓÖ¾ Clinical Chemistry ÉÏ£¬Í¬ÆÚ·¢±íÁ½Æª¹ØÓÚ¼¡¸Æµ°°×¼²²¡ÌØÒìÐÔÍ»ÆÆÐÔÑо¿µÄÂÛÎÄ¡£

    ³¤ÆÚÒÔÀ´£¬¼±ÐÔÐļ¡ËðÉ˺ÍÂýÐÔÐļ¡ËðÉ˵ÄÇø·ÖÊÇÐÐÒµºËÐÄÌôÕ½Ö®Ò»£¬½üÄêÀ´Êܵ½Ô½À´Ô½BGÕæÈ˹ÙÍøµÄ¹Ø×¢[1][2][3]¡£±¾´ÎÑо¿½á¹ûÏÔʾ£¬¼±ÐÔÐļ¡ËðÉ˺ÍÂýÐÔÐļ¡ËðÉ˵ļ¡¸Æµ°°×ÊͷŹæÂÉ´æÔÚÏÔÖø²îÒì¡£¶ÔÓÚ¼±ÐÔÐļ¡ËðÉË£¬¼¡¸Æµ°°× ITC ÈýÔª¸´ºÏÎïÓÅÏÈÊÍ·Å£¬ÔÚÑ­»·ÖÐÕ¼¼¡¸Æµ°°××ܸ´ºÏÎïµÄ±ÈÀý¸ü¸ß£»¶ÔÓÚÂýÐÔÐļ¡ËðÉË£¬ITC ÈýÔª¸´ºÏÎï±ÈÀýÏà¶Ô½ÏµÍ£¬¼¡¸Æµ°°×Ö÷ÒªÒÔÓÎÀëµÄ cTnT Ƭ¶ÎÐÎʽ´æÔÚ¡£

    ÕâÒâζ×Å£¬¼Ì 2023 ÄêÍ»ÆÆÐÐÒµÐÔÄܼ«ÏÞµÄ hs-cTnl ÎÊÊÀºó£¬BGÕæÈËÔÚ¸ßÃô¼¡¸Æµ°°×ÊͷŹæÂÉÓë¼²²¡Ïà¹ØÐÔÑо¿ÔÙ´ÎÈ¡µÃÖØ´óÍ»ÆÆ£¬ÎªÐÐÒµÌṩÐÂ˼·ºÍ¹¤¾ß¡£¼¡¸Æµ°°×ÈýÔª¸´ºÏÎï×÷ΪÐļ¡ËðÉ˵ĿìËÙÏìÓ¦±êÖ¾ÎÓÐÏ£Íû½øÒ»²½ÌáÉýÐĹ£Õï¶ÏЧÄܺÍЧÂÊ¡£¼¡¸Æµ°°×Ƭ¶Î»¯·ÖÎö°ïÖú¸ü¿ìËÙÇø·Ö·ÇÐĹ£µÄÂýÐÔÐļ¡ËðÉË»¼Õߣ¬¼õÉÙ»¼ÕßÔÚ¼±Õï¿ÆÁô¹Ûʱ¼ä£¬ÌáÉýÐØÍ´»¼Õß¼±ÕïÖÜתЧÂÊ¡£

    ´ÓÆ÷¹ÙÌØÒìÐÔ
    µ½¼²²¡ÌØÒìÐÔ

    Ð¡¸Æµ°°×£¨cTn£©£¬´Ó¸ù±¾ÉϸıäÁ˼±ÐÔ¹ÚÂö×ÛºÏÕ÷£¨ACS£©µÄÕïÁƸñ¾Ö£¬±»Ïà¹Ø¹ú¼ÊÖ¸ÄÏÁÐΪ¢ñ¼¶ÍƼö¡£È»¶ø£¬µ¼Ö¼¡¸Æµ°°×ÉÏÉýµÄ¼²²¡ÖÖÀà·±BGÕæÈ˹ÙÍø£¬Õâ¶ÔÆäÁÙ´²ÌØÒìÐÔÌá³ö¸ü¸ßµÄÒªÇó¡£BGÕæÈËЯÊÖÐÐҵר¼Ò£¬´ÓÆ÷¹ÙÌØÒìÐÔµ½¼²²¡ÌØÒìÐÔµÄÍ»ÆÆ£¬¿ªÆôÁ˸ü¼èÉîµÄ¼¼Êõ̽Ë÷Óë¿ÆÑй¥¼á¡£

    Ð¡¸Æµ°°×ÔÚѪ½¬ÖÐÒÔÊýÁ¿ÅÓ´ó¡¢ÐÎʽºÍ±ÈÀý²»Ò»µÄƬ¶Î´æÔÚ¡£Òò´Ë£¬ÔøÓпÆÑ§¼ÒÉèÏ룬Èç¹ûÄÜ׼ȷÀí½â¼¡¸ÆÆ¬¶ÎµÄ´æÔÚÐÎʽºÍ±ÈÀý£¬»òÐí¾ÍÄÜÇø·Öµ¼Ö¼¡¸Æµ°°×Éý¸ßµÄ¼²²¡Àà±ð[4][5]¡£

    »ùÓÚ½üÄêÀ´º£ëĶÔÐ¡¸Æµ°°×´úл¶¯Á¦Ñ§µÄÍ»ÆÆÐÔÑо¿£¬BGÕæÈ˽áºÏ×ÔÉíÊÔ¼Á¿ª·¢Æ½Ì¨µÄÓÅÊÆ£¬Éè¼Æ²¢¿ª·¢³öÕë¶Ô¼¡¸Æµ°°×²»Í¬Æ¬¶ÎÐÎʽµÄ¸ßÁéÃô¡¢¸ßÌØÒì¼ì²âÊÔ¼ÁÓë·½·¨£¬²¢ÓÉ´Ë¿ªÕ¹¼¡¸Æµ°°×¼²²¡ÌØÒìÐÔÑо¿¡£

    ³Ðǰ֮»Û
    ¹¹½¨È«ÐµÄÃâÒß¼ì²â¹¤¾ß

    ¹ýÍùÑо¿±íÃ÷£¬Ëæ×Å ACS ·¢²¡µÄ½øÕ¹£¬»¼ÕßѪҺÖдæÔÚBGÕæÈ˹ÙÍøÖÖ²»Í¬ÐÎʽµÄ¼¡¸Æµ°°×¸´ºÏÎ°üÀ¨ÒÔ²»Í¬·Ö×ÓÁ¿´æÔÚµÄ cTnI¸´ºÏÎïÒÔ¼°ÓÎÀë cTnT µÈ¡£

    Òò´Ë£¬Ñо¿ÍŶÓÕë¶ÔÐÔÉè¼ÆÁ˲»Í¬µÄÃâÒß¼ì²â·½·¨:

    (A) long-TITC complex£¬¼ì²â¾ßÓг¤Á´ cTnT µÄ ITC ÈýÔª¸´ºÏÎ

    (B) hs-totallTC complex£¬¼ì²â¾ßÓг¤Á´ºÍ»ò¶ÌÁ´ cTnT µÄ ITC ÈýÔª¸´ºÏÎ¼´×Ü ITC ÈýÔª¸´ºÏÎ

    (C) hs-cTnT£¬¼ì²â³¤Á´ cTnT µÄÈýÔª¸´ºÏÎïºÍÓÎÀë cTnT£»

    (D) hs-cTnl£¬¼ì²â³¤Á´ºÍ¶ÌÁ´ cTnT µÄÈýÔª¸´ºÏÎÒÔ¼° IC ¶þÔª¸´ºÏÎ¼´×Ü cTnI ¸´ºÏÎï¡£

    ÔÚʵÑéÖУ¬ÉÏÊöÊÔ¼ÁºÐµÄ¿Õ°×ÏÞ£¨LoB£©¡¢¼ì³öÏÞ£¨LoD£©¡¢¶¨Á¿¼ì³öÏÞ£¨LoQ£©¾ù´ïµ½¼«µÍµÄˮƽ£¬²»ÊܹÇ÷À¼¡¼¡¸Æµ°°×µÈÀàËÆÎï¸ÉÈÅ¡£Ñо¿ÍŶӽøÒ»²½½¨Á¢ÁËÕâЩcTnÊÔ¼ÁµÄµÚ 99 °Ù·Öλֵ²Î¿¼·¶Î§ÉÏÏÞ£¨99th URL£©£¬ÆäÔÚ 99th URL ´¦µÄ×Ü CV ¾ù <5%¡£

    Éýά¶´Ï¤¼¡¸Æµ°°×
    ±æÃ÷¼±ÐÔºÍÂýÐÔËðÉË

    ÍÅ¶Ó¶Ô 1 ÐÍÐ£ËÀ£¨T11£©¡¢ÐÄÔàÊÖÊõºÍÂýÐÔÐÄÔಡ£¨ÂýÐÔÐ¡»òÂýÐÔÐÄÁ¦Ë¥£©»¼ÕßµÄ cTn ³É·ÖºÍ¶¯Á¦Ñ§½øÐÐÉîÈëÑо¿¡£

    Ϊ½¨Á¢ cTn ³É·ÖÓëÁÙ´²Õï¶ÏÖ®¼äµÄ¹ØÏµ£¬
    ²ÉÓò»Í¬¸´ºÏÎïµÄ±ÈÖµ½øÐмÆË㣺
    R1 ´ú±í long-T ITC complex / hs-cTnI£¬
    R2 ´ú±í hs-total ITC complex / hs-cTnI£¬
    R3 ´ú±í hs-cTnT/ hs-cTnI¡£

    Ñо¿½á¹û±íÃ÷£¬ÔçÆÚ T1MI »¼ÕßÖÐ R1 ½Ï¸ß¡£
    ÕâÒ»ÏÖÏó±íÃ÷£¬Ðļ¡ËðÉ˼±ÐÔÆÚʱ cTn ¿ÉÄÜÒÔÏà¶ÔÍêÕûµÄ¼¡¸Æµ°°× ITC ÈýÔª¸´ºÏÎ¼´Long-TITC£©ÐÎʽÓÅÏÈÊÍ·Å¡£

    ͬÑù£¬¼±ÐÔÐÄÔàÊÖÊõºó»¼Õß cTn Ũ¶ÈÉý¸ß£¬R1 ½Ï¸ß£¬ËæºóѸËÙϽµ¡£ÕâÒ»Êý¾Ý½øÒ»²½Ö¤Êµ£¬Ð£ËÀ»òÍâÉ˵¼Öµļ±ÐÔÆÚÐļ¡ËðÉËÖУ¬¼¡¸Æµ°°×ÊÍ·ÅģʽÏà½ü£¬¾ùΪ Long-TITC Õ¼±È¸ü¸ß¡£

    ÔÚÂýÐÔÐÄÔಡ£¨ÈçÂýÐÔÐÄË¥»òÐ¡£©ÖУ¬cTn ×é³É³ÊÏÖÎȶ¨ºÍ½ÏµÍµÄR1ÒÔ¼°½Ï¸ßµÄ R3¡£Õâ±íÃ÷ÔÚÂýÐÔÐļ¡ËðÉË»òÐļ¡ËðÉ˷Ǽ±ÐÔÆÚµÄ³¡¾°Ï£¬ÑªÒºÑ­»·ÖÐµÄ cTn µÄ×é³ÉÓë¼±ÐÔÆÚ²»Í¬£¬³ÊÏÖ³ö Long-T ITC Õ¼±ÈµÍ£¬¶øË鯬»¯ cTnT Õ¼±ÈÔö¼ÓµÄÏÖÏó¡£

    ÓÉ´Ë¿´À´£¬ÔÚ¼±ÐÔÐļ¡ËðÉËÔçÆÚ£¬¼¡¸Æµ°°× ITC ÈýÔª¸´ºÏÎïÓÅÏÈÊÍ·Å£¬ÔÚÑ­»·ÖÐÕ¼¼¡¸Æµ°°××ܸ´ºÏÎïµÄ±ÈÖµ¸ß£»ÔÚÂýÐÔÐÄÔಡ»¼ÕßµÄѪҺÖУ¬¼¡¸Æµ°°×Ö÷ÒªÒÔÓÎÀëµÄ cTnT Ƭ¶ÎÐÎʽ´æÔÚ¡£ÕâÒ»·¢ÏÖÌáʾÁËBGÕæÈ˹ÙÍøÖÖ cTn ÐÎʽµÄ¶¯Á¦Ñ§²îÒìÓÐÖúÓÚÇø·Ö¼±ÐÔËðÉ˺ÍÂýÐÔ¼²²¡£¬ÆäÖи߱ÈÀýµÄ Long-T ITC ¸´ºÏÎﰵʾ·¢Éú¼±ÐÔËðÉË¡£ÒÔÉÏÑо¿Óë·¢ÏÖ£¬ÈÃÈ«ÐÐÒµ¿´µ½¼¡¸Æµ°°×¼²²¡ÌØÒìÐԵľ޴óDZÁ¦£¬ÎªºóÐø ACS ÔçÆÚÕï¶ÏÂõ³öÖØÒªÒ»²½¡£

    Kristin Moberg Aakre ½ÌÊÚ

    IFCC ÐÄѪ¹Ü±êÖ¾ÎïÁÙ´²Ó¦ÓÃίԱ»áÖ÷ϯ

    ÎÄÕÂÇø·ÖÁËÐ¡¸Æµ°°×µÄ²»Í¬¸´ºÏÎïºÍƬ¶Î£¬ÔÚδÀ´¿ÉÄܾßÓи߶ȵÄÁÙ´²ÒâÒå¡£

    Ñо¿¼ÙÉèÊǼ±ÐÔÐļ¡Ï¸°ûËðÉ˺ͻµËÀ½«µ¼Ö³¤ÐÎʽµÄÐ¡¸Æµ°°×ÊÍ·Å£¬¶øÂýÐÔÐļ¡ËðÉË»¼ÕßÓÉÓÚÐļ¡Ñ¹Á¦µ¼ÖµÄÐļ¡Ï¸°ûת»»ÂʸßÓÚ½¡¿µÈË£¬µ¼ÖÂÁ˼¡¸Æµ°°×Ƭ¶ÎµÄÊÍ·Å¡£

    ¶øÇø·ÖÕâÁ½ÖÖÇé¿öµÄÊÔ¼Á£¬¿ÉÒÔ°ïÖúÁÙ´²Ò½Éú¸ü¿ìµØÊ¶±ð¼±ÐÔÐļ¡ËðÉË£¬Õâ±Èµ±Ç°µÄ²ßÂÔ¾ßÓиü¸ßµÄÌØÒìÐÔ£¬Ò²Îª¼±ÐÔÐÄѪ¹ÜʼþÆÚ¼ä¼õÉÙÁ¬Ðø²ÉѪÌṩÁË¿ÉÄÜÐÔ¡£

    Fred S. Apple ½ÌÊÚ

    IFCC ÐÄѪ¹Ü±êÖ¾ÎïÁÙ´²Ó¦ÓÃίԱ»áǰÈÎÖ÷ϯ

    ×î½üÔÚ Clinical Chemistry ÔÚÏß·¢±íÁËÁ½ÆªÐÂÐÍÐÄÔàÉúÎï±êÖ¾ÎïÂÛÎÄ¡£

    ÕâЩÑо¿½ÒʾÁ˱íÕ÷ cTnI ºÍ cTnT ×é·ÖÔÚÇø·Ö¼±ÐÔºÍÂýÐÔÐļ¡ËðÉ˺ͼ²²¡µÄBGÕæÈ˹ÙÍøÖÖ²¡ÀíÉúÀíѧ²¡Òò·½Ã棨°üÀ¨²»Í¬Ð£ËÀÀàÐÍÖ®¼äµÄÊÍ·Åģʽ¡¢Çø·ÖÂýÐÔ¼²²¡ÖеÄÐÂËðÉËÒÔ¼°Ìá¸ß¼±ÕﻼÕßµÄÔçÆÚÅųýÌØÒìÐÔ£©¾ßÓо޴óµÄDZÁ¦¡£

    ÕÅÕæÂ· ½ÌÊÚ

    Î人ÑÇÖÞÐÄÔಡҽԺ¼ìÑé¿ÆÖ÷ÈÎ

    ÎÒÃÇÔÚ Clinical Chemistry ͬÆÚ·¢±íµÄÁ½ÆªÑо¿£¬´òÆÆÁË¡°Ò»ÖÖ´ý²âÎï=Ò»ÖÖ¼²²¡=Ò»ÖÖ¼ì²â¡±µÄ¶¨Ê½£¬ÎªÊµÏÖ¼²²¡×¼È·Õï¶Ï£¬ÌṩÕë¶Ôͬһ±êÖ¾ÎïµÄ²»Í¬Æ¬¶ÎµÄ¼ì²â£¬ÒÔ´ËÀ´Åжϲ»Í¬¼²²¡×´Ì¬Ï»ò¼²²¡µÄ²»Í¬½×¶ÎÒýÆð²»Í¬µÄ¼¡¸Æµ°°×ÊÍ·ÅÆ¬¶Î×éºÏµÄÌØÕ÷£¬Â䵨ÁË¡°¼¡¸Æµ°°×Ö¸ÎÆÍ¼Æ×¡±¼ì²â¡£

    ÎÒÃÇ·¢ÏÖÔÚ¼±ÐÔÐļ¡ËðÉËÔçÆÚ£¬¼¡¸Æµ°°× ITC ÈýÔª¸´ºÏÎïÓÅÏÈÊÍ·Å£¬ÔÚÑ­»·ÖÐÕ¼¼¡¸Æµ°°××ܸ´ºÏÎïµÄ±ÈÖµ¸ß£»ÔÚÂýÐÔÐÄÔಡ»¼ÕßµÄѪҺÖУ¬¼¡¸Æµ°°×Ö÷ÒªÒÔÓÎÀëµÄ cTnT Ƭ¶ÎÐÎʽ´æÔÚ¡£

    ÕâЩ±ä»¯¹æÂɵķ¢ÏÖÓÐÍûΪÏÂÒ»²½¼ø±ð¼±¡¢ÂýÐÔÐļ¡ËðÉË¡¢ÐÄÍâ¿ÆÊÖÊõΧÊõÆÚMIÔçÆÚÅжÏ¡¢Éö¹¦ÄÜË¥½ß»¼Õß MI Õï¶ÏÄÜÁ¦µÄÌá¸ßµÈ·½Ã棬´øÀ´¸ïÃüÐÔÍ»ÆÆ¡£

    ȫи߶È£¬´ÓÐijö·¢£¬Ö»ÎªÈ·ÐÅ¡£

    δÀ´BGÕæÈ˽«ÁªºÏ¸üBGÕæÈ˹ÙÍø×¨ÒµÁ¦Á¿£¬Ì½Ë÷cTn³É·ÖºÍ¶¯Á¦Ñ§ÔÚÁÙ´²Ð§ÄÜ·½ÃæµÄÉîÈëÓ¦Óá£

    ·¢±íÎÄÕÂÌâÄ¿£º

    [1] Li L, Liu Y, Katrukha IA, et al. Design and Analytical Evaluation of Novel Cardiac Troponin Assays Targeting Multiple Forms of the Cardiac Troponin I-Cardiac Troponin T-Troponin C Complex and Fragmentation Forms. Clin Chem. Published online December 19, 2024. doi:10.1093/clinchem/hvae182

    [2] Li L, Liu Y, Katrukha IA, et al. Characterization of Cardiac Troponin Fragment Composition Reveals Potential for Differentiating Etiologies of Myocardial Injury. Clin Chem. Published online December 17, 2024. doi:10.1093/clinchem/hvae200

    ÒýÓÃ×ÊÁÏ£º

    [1] Katrukha IA, Katrukha AG. Myocardial injury and the release of troponins I and T in the blood of patients. Clin Chem 2021;67:124-30.

    [2] Damen SAJ, Cramer GE, Dieker H-J, Gehlmann H, Ophuis TJMO, Aengevaeren WRM, et al. Cardiac troponin composition characterization after non ST-elevation myocardial infarction: relation with culprit artery, ischemic time window, and severity of injury. Clin Chem 2021;67:227-36.

    [3] Airaksinen KEJ, Aalto R, Hellman T, Vasankari T, Lahtinen A, Wittfooth S. Novel troponin fragmentation assay to discriminate between troponin elevations in acute myocardial infarction and end-stage renal disease. Circulation 2022;146:1408-10.

    [4] Labugger R, Arrell DK, Van Eyk JE. Cardiac troponins: Exploiting the diagnostic potential of disease-induced protein modifications. In: Wu AHB, editor Cardiac markers Totowa, NJ: Humana Press; 2003. p. 125-38.

    [5] ¡¶ÐÄÔà±êÖ¾Îï µÚ2°æ¡·ÈËÃñÎÀÉú³ö°æÉ磬2009 Alan H.B.WuÔ­Öø£»×ÞÐÛ£¬Å˰ØÉêÖ÷Òë¡£

    false
    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿